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abstract
PURPOSE Multidisciplinary cancer care is currently considered worldwide as standard for the management of
patients with cancer. It improves patient diagnostic and staging accuracy and provides patients the beneﬁt of
having physicians of various specialties participating in their treatment plan. The purpose of this study was to
describe the proﬁle of patients discussed in the Tikur Anbessa Multidisciplinary Tumor Board (MTB) and the
potential beneﬁts brought by multidisciplinary care.
METHODS The study involved the retrospective assessment of all patient cases presented to the Tikur Anbessa
Hospital colorectal cancers MTB between March 2016 and November 2017. The data were collected from the
MTB medical summary documents and were analyzed using SPSS version 20 (SPSS, Chicago, IL).
RESULTS Of 147 patients with colorectal cancer, 96 (65%) were men. The median age at presentation was
46 years (range, 17-78 years). The predominant cancer was rectal (n = 101; 69%), followed by colon (n = 24;
16%). Of these, 68 (45%) and 22 (15%) had stage III and IV disease, respectively, on presentation to the MTB.
The oncology department presented the majority of the patients for discussion. Most patients had undergone
surgery before theMTB discussion but had no proper preoperative clinical staging information. Themajority of
patients with rectal cancer treated before the MTB discussion had undergone surgery upfront; however, most
of the patients who were treatment naive before MTB received neoadjuvant chemoradiotherapy before
surgery.
CONCLUSION Decisions made by tumor boards are more likely to conform to evidence-based guidelines than are
those made by individual clinicians. Therefore, early referral of patients to MTB before any treatment should be
encouraged. Finally, other hospitals in Ethiopia should take a lesson from the Tikur Anbessa Hospital colorectal
cancers MTB and adopt multidisciplinary cancer management.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Cancer continues to be a medical challenge worldwide.
It has become one of the leading causes of morbidity
and mortality, particularly in low- and middle-income
countries, where 60% of the world’s total new patient
cases are diagnosed.1 Cancer is a complex disease that
is rarely detected, diagnosed, and adequately treated by
a single physician or discipline; hence, a multidisci-
plinary approach is required.2Multidisciplinary care can
be broadly deﬁned as an integrated team approach to
health care in which medical and allied health care
professionals consider all relevant treatment options
and collaboratively develop an individual treatment plan
for each patient.3 Multidisciplinary care can be de-
livered either by specialized units or by multidisciplinary
tumor boards (MTBs).2,4 The initial evaluation and
treatment decisions are the most critical to the outcome
of a patient, andmultidisciplinary care provides patients
with cancer the potential beneﬁt of having physicians of
various specialties participate in their treatment
planning.5
There is evidence that multidisciplinary cancer care
improves patient diagnostic accuracy, staging accu-
racy, and overall survival.6-10 This is why multidisci-
plinary cancer care is currently considered worldwide
as standard for the management of patients with
cancer. Increasingly, multidisciplinary care is prac-
ticed through MTBs or multidisciplinary teams (MDT)
meetings, which are formal meetings usually held
regularly, often on a weekly basis.4 MTB or MDT
meetings bring together physicians from differ-
ent disciplines (oncologists, radiologists, surgeons,
pathologists) and various members of the health care
team who are involved in a patient’s care, for inter- and
intradisciplinary discussions. These discussions help
in planning the necessary diagnostics or treatment
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strategy for individual patients on the basis of the available
scientiﬁc evidence and resources, with the aim of stan-
dardizing and improving outcomes.11
As with the management of other cancers, managing co-
lorectal cancer through a single treatment is difﬁcult. Be-
cause treatment options for colorectal cancer have
increased rapidly in recent decades, establishing anMTB is
crucial to fulﬁlling the requirements of multimodal treat-
ments. Because of this, the MTB approach for colorectal
cancer has been widely accepted and is recommended
worldwide as the standard of care in current practice.12-14
The purpose of this study was to describe the proﬁle of
patients discussed in the Tikur Anbessa MTB and the
potential beneﬁts brought by multidisciplinary care.
METHODS
Study Setting
Tikur Anbessa Hospital is the largest referral and teaching
hospital in Ethiopia. Until now, it has been the only center in
which patients with cancer are treated at a tertiary level and
where access to chemotherapy and radiotherapy are
available. The Department of Clinical Oncology has two
radiotherapy machines (cobalt-60), 36 beds in the impa-
tient chemotherapy ward, and 12 outpatient chemotherapy
beds. Six clinical oncologists serve the department.
Patients who need chemotherapy and radiotherapy are
referred to this hospital from the whole country. The De-
partment of Surgery has two colorectal surgeons. Currently,
the Department of Radiology is equipped with two com-
puted tomography scans and one magnetic resonance
imaging unit. The Department of Pathology provides his-
tologic results mainly on the basis of microscopic mor-
phology. Immunohistochemical tests are performed
intermittently on patients with malignant disease.
Tikur Anbessa Colorectal Cancers MTB
The Tikur Anbessa Hospital colorectal cancers MTB,
established on May 2014, is the ﬁrst tumor board in
Ethiopia. It is composed of surgeons specializing in on-
cologic interventions (colorectal surgeons and a hep-
atobiliary surgeon), clinical oncologists, and radiologists.
Residents from various specialties also attend the tumor
board as a part of their education. The Tikur Anbessa
Hospital Colorectal Cancers MTB conducts a meeting once
a week, every Friday.
In May 2016, the Tikur Anbessa Hospital colorectal can-
cers MTB was reorganized to facilitate the board’s effec-
tiveness. The Department of Clinical Oncology assigns the
coordinator for all activities of the tumor board. The basic
role of the coordinator is to accept patient cases selected
from each department for tumor board discussion and to
send, via e-mail, the medical summary of each of the
selected patient cases to all attending physicians 1 day
before the meeting to keep them informed. In addition,
presenting the patient cases, moderating the meeting, and
recording the discussion and decisions after discussion are
the responsibilities of the coordinator. After each session,
the decisions made at the meeting are sent to all attending
physicians by e-mail, and the printout is ﬁled in each
department for future reference. The patients are managed
according to the agreed-on consensus.
Study Design
The study involved assessment of all patients presented to the
Tikur Anbessa Hospital colorectal cancers MTB between
March 2016 and November 2017. We retrospectively eval-
uated all patients presented to the tumor board from the
documents containing the medical summary of each se-
lected patient and the decisions made. Documentation
contains data on cancer type, cancer histology, initial staging
data before MTB presentation, previous therapeutic pro-
cedures, and tumor board recommendation. The staging was
made according the TNM staging system of the American
Joint Committee on Cancer, 7th edition.15 The conﬁdentiality
of the patient and the attending physician was maintained
during data collection and analysis. The descriptive analysis
was performed using SPSS version 20 software.
The study was conducted according to Addis Ababa Uni-
versity ethical guidelines, and approval was received from
the Department of Clinical Oncology Research Committee.
The study was conducted without individual informed
consent, because it relied on retrospective data collected as
part of routine patient care and the data were anonymous.
RESULTS
One hundred ﬁfty-four patients were presented between
March 2016 and November 2017 to Tikur Anbessa Hos-
pital colorectal cancers MTB. Of these, 147 patients (95%)
had colorectal or anal cancers and seven (5%) had cancers
of the hepatobiliary system.
Of the 147 patients with colorectal cancer, 96 (65%) were
men. The median age at presentation was 46 years (range,
17-78 years). The anatomic site of primary cancer was pre-
dominantly rectal (n = 101; 69%), followed by colon (n = 24;
16%), rectosigmoid junction cancer (n = 13; 9%), anal (n = 6;
4%), and synchronous colon and rectal (n = 3; 2%; Fig 1).
Of the patients with colorectal and anal cancer, 68 (45%)
were diagnosed with stage III, 20 (14%) with stage II, 22
(15%) with stage IV, and three (2%) with stage I cancer on
presentation to the tumor board. The rest (n = 34; 23%)
had incomplete information for staging (Fig 2).
The histologic diagnosis of all patients with colorectal
cancer, including anal cancer, was mainly adenocarci-
noma (n = 136; 93%). There were six patient cases of
squamous cell carcinoma (4%), and the other histologies
included carcinoid tumor, GI stromal tumor, melanoma,
myxiod ﬁbrosarcoma, and liposacroma (one patient case
each [1%]; Table 1).
Of the 147 patient cases, physicians from the Department
of Clinical Oncology presented 127 patients (86%) for MTB
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discussion, whereas physicians from the Department of
Surgery presented 20 patients (14%). All physicians par-
ticipated in patient case discussions and in the making of
management plans.
Of the 147 patients, 66 (45%) had received oncologic
treatment before their presentation to the MDT; 81 (55%)
had not received any kind of oncologic treatment before
and they presented as new patient cases.
Characteristics of Patients Who Received Oncologic
Treatment Before Presentation to Tumor Board
Of the 66 patients who had received treatment before
presentation to theMTB, the anatomic location of the tumor
was 37 (56%) rectal, 18 (27%) colon, nine (14%) rec-
tosigmoid, and two (3%) anal (Table 2). The prior oncologic
treatment consisted of radical operation for 58 patients
(88%), neoadjuvant chemotherapy for six (9%; all patient
cases of rectal cancer), and tumor resection for two (3%).
The majority of patient cases (n = 32; 48%) did not have
complete information for proper staging, mainly because
there was incomplete preoperative clinical stage in-
formation on the referral paper. In addition, none had
postoperation nodal status information and of these, seven
did not have postoperation pathologic tumor stage in-
formation either. Thirty-four patients (52%) had adequate
information for staging; of these, 15 patients had stage III,
11 patients had stage IV, seven had stage II, and one had
stage I cancer at the time of presentation.
Among 58 patients for whom radical surgery was per-
formed, 31 (64%) surgeries were rectal, 18 (31%) colonic,
and nine (16%) rectosigmoid. Of these, 34 patients (58%)
underwent surgery on an elective basis, ﬁve (9%)
underwent surgery on an emergency basis, and all were
colon cancers with obstruction. For the remaining 19
patients (33%), the mode of surgical presentation was not
documented. Thirty-one patients with rectal cancer had
undergone upfront surgery without neo-adjuvant che-
moradiotherapy. The most common operation performed
for those with rectal cancer was abdominoperineal re-
section in 22 patients (71%) and lower anterior resection
in eight (26%), and in one patient case, the cancer was
known to be inoperable intraoperatively. For nine patients
with rectosigmoid junction tumor, lower anterior resection
was performed for seven patients and hemicolectomy for
two patients. Hemicolectomy was the procedure per-
formed in all 18 patients who underwent surgery for colon
cancer. From the pathology reports of the patients who
underwent surgery, 11 (19%) had involved surgical
margin status and 11 (19%) were free of tumor surgical
margin status. However, 36 patients had no documen-
tation of surgical margin status. Among patients who
underwent radical surgery before MDT, local recurrence
was the reason for presentation in 26 (45%).
Of all 66 patients who received prior oncologic therapy,
57 (86%) were presented to the MTB by the Department
of Clinical Oncology and nine (14%) by the Department
of Surgery. After discussion, the tumor board decision
was palliative chemotherapy for 36 patients (55%),
adjuvant chemotherapy for 21 (32%), adjuvant radio-
therapy for 18 (27%), surgery for palliative purpose for
11 (17%), and palliative radiotherapy for seven (11%).
For a number of patients, various combinations of the
previously mentioned individual treatment plans were
selected.
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FIG 1. Distribution of patient cases by anatomic site of the primary cancer.
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FIG 2. Distribution of patient cases by American Joint Committee
on Cancer–stage of disease at the time of tumor board presentation.
N/A, not available.
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Characteristics of Patients Who Did Not Receive
Oncologic Treatment Before Presentation to Tumor Board
Eighty-one patients were presented to the tumor board as
new patient cases before any oncologic therapy had been
received (Table 2). Of these, 64 patients (79%) had rectal
cancer, seven (9%) had colon cancer, four (5%) had anal
and rectosigmoid tumors, and two (2%) had synchronous
colon and rectal tumors. Of all the patients, 79 (98%) were
properly staged as per the American Joint Committee on
Cancer, 7th edition staging manual and two did not have
proper staging. Of these 79 patients, 52 (64%) had stage
III, 13 (16%) had stage II, 12 (15%) had stage IV, and two
(2%) stage I disease.
After discussion in the MTB, the decisions were neo-
adjuvant chemoradiotherapy followed by surgery for
45 patients (56%); palliative chemotherapy for 17 patients
(21%) and of these, palliative radiotherapy for 10 patients
(12%) as well; upfront radical surgery followed by adjuvant
chemotherapy or radiotherapy for 16 patients (20%); and
deﬁnitive chemoradiotherapy for four patients (5%).
Of all 81 patients who had not received prior oncologic
therapy, 70 (86%) were presented to the MTB by the
Department of Clinical Oncology; the Department of Sur-
gery presented 11 patients (14%).
DISCUSSION
In this study, we have summarized the experience of the
ﬁrst MTB in Ethiopia during its ﬁrst year of establishment.
We noted from our study that two thirds of patient cases
presented to the tumor board were patients with rectal
cancer and one third were patients with colonic cancer.
The relative number of patient cases of colon cancer versus
rectal cancer was found to be opposite to those presented
in Western countries.16 This is possibly because the current
management recommendation for rectal cancer in many
patient cases requires combination radiotherapy and
chemotherapy,13 which is only available in a specialized
hospital, and this leads to more common referral to the
MTB. Nevertheless, in Ethiopia, speciﬁc oncologic therapy
including chemotherapy is only possible within specialized
centers. It may be hypothesized that a majority of patients
with colon cancer are not presented to tumor boards or do
not receive necessary adjuvant chemotherapy. Conversely,
previous studies of pathologic biopsies of colorectal can-
cers in Ethiopia reported that two thirds of the patient cases
were rectal cancer and one third were colonic cancer.17
This is consistent with our ﬁndings. Other studies from
surgical departments have also shown that rectal cancer
comprises one half of all of surgeries for colorectal cancer,
which is still a higher percentage than that reported by
Western countries.18 The other ﬁnding of our study, which
is different from the ﬁndings of Western studies, was the
younger age at presentation (ie, a median age of 46 years).
Other studies on colorectal cancer in Ethiopia have re-
ported a similar median age at presentation.17,18 However,
additional study is mandatory to characterize the current
epidemiology of colorectal cancer in Ethiopia.
Evidence indicates that decisions made by MTBs are more
likely to conform to evidence-based guidelines than are
those made by individual clinicians.19-22 We also found that
the management plan for patient cases presented to tumor
boards from the beginning, as new patients, conformed
more to an evidence-based approach, compared with
those patients who had received treatment before MTB
presentation. For example, with regard to proper staging
and the provision of neoadjuvant chemoradiotherapy for
patients with rectal cancer, those patients who were pre-
sented early to the MTB had better treatment plans, as per
current guidelines. More than one half of patients (52%)
who underwent surgery before the tumor board had in-
adequate staging information compared with those patient
cases presented initially, where 98% had complete clinical
staging. It is obvious that accurate tumor staging for co-
lorectal cancer, as well as other types of cancer, is critical to
deﬁne appropriate management, to facilitate communi-
cation between physicians, to provide a basis for stratiﬁ-
cation and analysis of treatment results in studies, and to
provide some prognostic information for patients and their
families.12,13,23 Therefore, properly staged patients will have
a better chance of a proper treatment plan, which will result
in better patient selection and better oncologic outcome.24
Among patients with rectal cancer who were presented as
new patients to the tumor board, most (70%) planned to
have neoadjuvant chemoradiotherapy followed by surgery.
In contrast, in previously treated patients, only 16% were
able to receive neoadjuvant chemoradiotherapy, and others
underwent surgery up front. Becausemost of these patients
were at a locally advanced stage, preoperative chemo-
radiotherapy was preferred for a better oncologic outcome,
especially in terms of the local failure control rate.13,25-29
This can be illustrated by our ﬁnding that the postsurgical
local recurrence rate is 45% among those who underwent
surgery before tumor board presentation. However, al-
though we cannot compare these patients with the patients
managed after tumor board discussion right from the be-
ginning, it is an obviously unacceptably higher recurrence
rate than those of older Western studies that reported
a local recurrence rate of , 13%.30 It is important to note
TABLE 1. Distribution of Histologic Diagnosis of Patients With
Colorectal Cancer Presented at Tumor Board
Histology No. (%)
Adenocarcinoma 136 (93)
Squamous cell carcinoma 6 (4)
Carcinoid tumor 1 (1)
GI stromal tumor 1 (1)
Melanoma 1 (1)
Myxiod ﬁbrosarcoma 1 (1)
Liposarcoma 1 (1)
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that the higher recurrence rate is not merely a result of the
absence of an MTB presentation. It could be caused by
poor patient selection, because one half of patient cases
with recurrence had no proper staging. Other possible
reasons could be poor surgical technique or a long waiting
time for chemoradiotherapy because of the limited access
to radiotherapy and chemotherapy in Ethiopia.31 However,
the ﬁndings show that patients treated after MTB discus-
sion from the beginning had a better management plan as
per guidelines.13,26
This study shows that the colorectal cancers MTB in Tikur
Anbessa Hospital is used as a forum for group consultations
and multidisciplinary patient management. We believe this
is a positive trend toward better and multidisciplinary care
of patients with cancer in the hospital. Although clinical
oncologists presented the majority of the patient cases,
surgeons and radiologists were essential in discussions and
ﬁnal management plans. All members of the tumor board
were important contributors to the success of the tumor
board by virtue of case preparation, presentation, discus-
sion, and the making of management plans. The tumor
board discussion also became a good platform for teaching
residents and junior doctors. It also creates good in-
terdepartmental relationships, and it has become a source
for joint research and clinical trials. However, the low rate of
referral from the surgical department, poor adherence to
guidelines for those who underwent surgery before pre-
sentation to the MTB, and poor documentation of ﬁndings
are challenges that must be addressed. In addition, the
lack of participation by pathologists is one of the de-
ﬁciencies of this tumor board. Pathologists may not have
participated because of other overlapping obligations,
including conducting procedures or teaching. However,
we recommend that in addition to the already existing
TABLE 2. Characteristics of Patients Who Received Treatment Before MTB v Treatment-Naive Patients
Characteristic of Patients
Patients Who Received Treatment
Before MTB, No. (%)
Treatment-Naive Patients
Before MTB, No. (%) P
No. of patients 66 81
Anatomic location of the tumor
Rectal 37 (56) 64 (79) .003*
Colon 18 (27) 7 (9)
Rectosigmoid 9 (14) 4 (5)
Anal 2 (3) 4 (5)
Upfront oncologic treatment
Radical surgery 58 (88) 16 (20) , .001*
Neoadjuvant chemoradiotherapy 6 (9) 45 (56)
Deﬁnitive chemoradiotherapy None 4 (5)
Tumor resection 2 (3) None
Completeness of staging work-up/information
Complete 34 (52) 79 (98) , .001†
Incomplete 32 (48) 2 (2)
Local recurrence rate (after radical surgery) 26 (45) Cannot be determined —
Patient case presenting department
Clinical oncology 57 (86) 70 (86) .992†
Surgery 9 (14) 11 (14)
Post-MTB discussion treatment recommendations
Neoadjuvant chemoradiotherapy followed by radical surgery 6 (9) 45 (56) , .001†
Upfront surgery followed by adjuvant chemotherapy 21 (32) 16 (20)
Upfront surgery followed by adjuvant radiotherapy 18 (27) None
Palliative chemotherapy 36 (55) 17 (21)
Palliative radiotherapy 7 (11) 10 (12)
Surgery for palliative purpose 11 (17) None
Deﬁnitive chemoradiotherapy None 4 (5)
Abbreviation: MTB, multidisciplinary tumor board.
*Fisher’s exact test.
†Pearson χ2 test.
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physicians, pathologists and other specialists such as gas-
troenterologists and supporting nurse staff participate in
discussions and decisionmaking, to expandmultidisciplinary
care to all patients with colorectal cancer and to improve the
quality of service. Proper training regarding the current
management guidelines for surgeons and other relevant
stakeholders and placing mechanisms to strengthen the
referral system between departments must be emphasized.
We believe the multidisciplinary cancer management
started by the Tikur Anbessa Hospital colorectal cancers
MTB is highly beneﬁcial to the hospital and its patients. It
should be expanded to other types of cancer as well. It is
also important for other hospitals in Ethiopia to learn from
the practice of this tumor board and to establish multi-
disciplinary cancer management to improve the quality of
service for their patients.
Because the patient cases presented to the Tikur Anbessa
Hospital colorectal cancers MTB for discussion were
selected patients, the clinicopathologic features we found
during our analysis may not represent the actual charac-
teristics of patients with colorectal cancer in this country.
The other limitation of our study is that the information
included concerned mainly the characteristics of patients
at their ﬁrst tumor board presentation, not the outcome after
treatment.
The MTB enhanced integrated cancer care and resulted
in better staging accuracy and management. Decisions
made by the MTB are more likely to conform to evidence-
based guidelines than are those made by individual cli-
nicians. Therefore, early referral of patients to the MTB
before any treatment must be practiced by responsible
physicians to result in better oncologic outcomes. Finally,
other hospitals in Ethiopia should take a lesson from
the Tikur Anbessa Hospital colorectal cancers MTB and
adopt multidisciplinary cancer management for all pa-
tients with cancer.
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